GlassScriptPhysician profile
Kelly Dayton
NPI 1801311170
$7,343.26
in general payments reported to CMS, 2019-2025
39 companies · $1,986 in 2025
The $1,986 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,037 · 2022: $967 · 2023: $1,588 · 2024: $1,766 · 2025: $1,986.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,254 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,254.28 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,441.54 | 2021-2025 | |
| Novo Nordisk INC | $1,269.67 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $627.37 | 2021-2025 | |
| Lilly USA, LLC | $574.73 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $441.57 | 2021-2024 | Jardiance, Synjardy, Tradjenta |
| Astellas Pharma US INC | $400.01 | 2021-2025 | Veozah |
| Exact Sciences Corporation | $308.50 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $266.15 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $195.03 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Janssen Pharmaceuticals, INC | $179.16 | 2021-2025 | Xarelto, Spravato |
| Abbott Laboratories | $177.04 | 2021-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Alkermes, INC. | $127.61 | 2022-2024 | Vivitrol, Vivitrol |
| Amgen INC. | $121.00 | 2021-2025 | Otezla, Repatha, Otezla |
| Harmony Biosciences LLC | $118.50 | 2021 | |
| Axsome Therapeutics, INC. | $116.74 | 2024-2025 | Auvelity |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Dayton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.